Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
PROZAC WEEKLY is a delayed-release oral capsule formulation of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) approved in 2001 for depression and related psychiatric conditions. The weekly dosing regimen is designed to improve patient adherence compared to daily formulations. It represents a lifecycle extension of the original PROZAC brand.
As LOE approaches, the brand team is likely consolidating headcount and shifting focus to generic transition planning and portfolio defense.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PROZAC WEEKLY roles are declining in availability as the product approaches LOE; positions emphasize brand defense, generic transition planning, and retention of remaining market share rather than expansion or innovation. This is a consolidation-phase career opportunity most relevant to professionals seeking experience in mature brand management or post-exclusivity strategy.
Worked on PROZAC WEEKLY at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.